Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma-Reference-Cited by-同舟云学术

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma

Published:2017-11-09 Issue:24 Volume:1 Page:2247-2256
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Green Damian J.¹²^ORCID,Maloney David G.¹²^ORCID,Storer Barry E.¹³,Sandmaier Brenda M.¹²^ORCID,Holmberg Leona A.¹²^ORCID,Becker Pamela S.¹²^ORCID,Fang Min¹,Martin Paul J.¹²^ORCID,Georges George E.¹²^ORCID,Bouvier Michelle E.¹,Storb Rainer¹²^ORCID,Mielcarek Marco¹²^ORCID

Affiliation:

1. Division of Clinical Research, Fred Hutchinson Cancer Research Center,

2. Department of Medicine, and

3. Department of Biostatistics, University of Washington, Seattle, WA

Abstract

Key Points Patients with high-risk multiple myeloma have a median survival of <3 years. Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy improves survival in these patients.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/24/2247/879039/advances010686.pdf

Reference51 articles.

1. Proteasome inhibitors in the treatment of multiple myeloma;Shah;Leukemia,2009

2. Daratumumab, bortezomib, and dexamethasone for multiple myeloma;Palumbo;N Engl J Med,2016

3. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma;Dimopoulos;N Engl J Med,2016

4. A phase 2 study of bortezomib in relapsed, refractory myeloma;Richardson;N Engl J Med,2003

5. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression;Orlowski;J Clin Oncol,2007

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years;Frontiers in Oncology;2024-07-31

2. HCT: Historical Perspective;The EBMT Handbook;2024

3. Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma;International Journal of Hematology;2023-04-15

4. Experts’ consensus on the definition and management of high risk multiple myeloma;Frontiers in Oncology;2023-01-23

5. Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD;Transplantation and Cellular Therapy;2023-01